Blocking TNFα attenuates progressive cartilage matrix degradation in inflammatory arthritis

Exp Ther Med. 2021 Aug;22(2):808. doi: 10.3892/etm.2021.10240. Epub 2021 May 27.

Abstract

Because damage to hyaline cartilage is irreversible, relieving progressive cartilage destruction is an important therapeutic approach for inflammatory arthritis. In the present study, human hyaline chondrocytes were isolated from total knee replacements of 15 patients with osteoarthritis (OA) and three with rheumatoid arthritis (RA). Synovial fluid of OA (n=25) and RA (n=34) were collected to measure tumor necrosis factor α (TNFα) using ELISA. Consistent with previous studies, the synovial fluid exhibited high TNFα levels and hyaline cartilage was severely destroyed in patients with RA. TNFα-treated chondrocytes were used as model for inflammatory arthritis. TNFα did not influence proliferation or extracellular matrix expression in chondrocytes, but induced matrix metalloproteinase (MMP)1, 3 and 13 expression levels in chondrocytes, which was accompanied by activation of nuclear factor-κB signaling. During chondrogenic differentiation, TNFα attenuated mRNA expression levels of anabolic factors (collagen type 2 and aggrecan) and enhanced mRNA expression of catabolic factors (MMP1, MMP3 and MMP13) in chondrocytes. Moreover, anti-TNFα agents (Golimumab) inhibited the TNFα-induced metabolic shift in chondrocytes and chondrogenic differentiation. The present study revealed a mechanism by which TNFα may induce metabolic shift in chondrocytes, leading to progressive chondrocyte destruction.

Keywords: TNFα; anti-TNFα inhibitor; chondrocytes; chondrogenic differentiation; inflammatory arthritis; metabolic shift.

Grants and funding

Funding: The present study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Science, ICT, and Future (grant nos. NRF-2016R1A2B4008606 and 2019R1A2C2004214). It was also supported by a Korea Health Technology R&D grant through the Korea Health Industry Development Institute, which is funded by the Ministry of Health and Welfare, Republic of Korea (grant no. HI17C0888).